



# Pharmacy Interoperability and Emerging Therapeutics Task Force 2023 Meeting #1

Shelly Spiro, Co-Chair

Hans Buitendijk, Co-Chair

June 21, 2023





# Call to Order/Roll Call

Mike Berry, Designated Federal Officer, ONC

# Pharmacy Interoperability and Emerging Therapeutics Task Force 2023 Roster



Name	Organization	Name	Organization
<b>Hans Buitendijk* (Co-Chair)</b>	<b>Oracle Health</b>	<b>Shelly Spiro (Co-Chair)</b>	Pharmacy HIT Collaborative
Pooja Babbrah	Point-of-Care Partners	Deven McGraw*	Invitae Corporation
Chris Blackley	Prescriptive North Dakota Health Information Network	Ketan Mehta	Micro Merchant Systems
Shila Blend*		Justin Neal	Noble Health Services Dell Medical School, University of Texas at Austin
David Butler	Curatro, LLC Texas Department of State Health Services	Eliei Oliveira*	
Steven Eichner	MCG Health, part of the Hearst Health network	Naresh Sundar Rajan*	CyncHealth
Rajesh Godavarthi*	Center for Disease Control and Prevention	Scott Robertson	Bear Health Tech Consulting
Adi V. Gundlapalli**		Alexis Snyder*	Individual
Jim Jirjis*	HCA Healthcare	Fillipe Southerland*	Yardi Systems, Inc.
Summerpal Kahlon	Rocket Health Care	Christian Tadrus	Community Pharmacy Owner
Steven Lane*	Health Gorilla Department of Veterans Health Affairs	Sheryl Turney*	Elevance Health
Meg Marshall**		Afton Wagner	Walgreens
Anna McCollister*	Individual		

# Agenda

**10:30 AM**

## **Call to Order/Roll Call**

- Mike Berry, Designated Federal Officer, ONC

**10:35 AM**

## **Opening Remarks/Task Force Introductions**

- Shelly Spiro, Co-Chair
- Hans Buitendijk, Co-Chair

**10:55 AM**

## **Task Force Charge, Timeline and Work Plan**

- Tricia Lee Rolle, Senior Advisor, ONC
- Shelly Spiro, Co-Chair

**11:10 AM**

## **Task Force Expectations on Recommendations**

- Hans Buitendijk, Co-Chair

**11:15 AM**

## **SHORT-TERM Public Health, Emergency Use Authorizations, and Prescribing Authorities**

- Shelly Spiro, Co-Chair
- Hans Buitendijk, Co-Chair

**11:50 AM**

## **Public Comment**

- Mike Berry, Designated Federal Officer, ONC

**11:55 AM**

## **Task Force Work Planning**

- Shelly Spiro, Co-Chair
- Hans Buitendijk, Co-Chair

**12:00 PM**

## **Adjourn**



# Opening Remarks/Task Force Introductions

Shelly Spiro, Co-Chair

Hans Buitendijk, Co-Chair

# Pharmacy Interoperability and Emerging Therapeutics Task Force 2023 Roster

(State name, organization, and title/role – please limit to 20 seconds)

Name	Organization	Name	Organization
Hans Buitendijk* (Co-Chair)	Oracle Health	Shelly Spiro (Co-Chair)	Pharmacy HIT Collaborative
Pooja Babbrah	Point-of-Care Partners	Deven McGraw*	Invitae Corporation
Chris Blackley	Prescriptive	Ketan Mehta	Micro Merchant Systems
Shila Blend*	North Dakota Health Information Network	Justin Neal	Noble Health Services Dell Medical School, University of Texas at Austin
David Butler	Curatro, LLC	Eliel Oliveira*	CyncHealth
Steven Eichner	Texas Department of State Health Services	Naresh Sundar Rajan*	Bear Health Tech Consulting
Rajesh Godavarthi*	MCG Health, part of the Hearst Health network	Scott Robertson	Individual
Adi V. Gundlapalli**	Center for Disease Control and Prevention	Alexis Snyder*	Yardi Systems, Inc.
Jim Jirjis*	HCA Healthcare	Fillipe Southerland*	Community Pharmacy Owner
Summerpal Kahlon	Rocket Health Care	Christian Tadrus	Elevance Health
Steven Lane*	Health Gorilla	Sheryl Turney*	Walgreens
Meg Marshall**	Department of Veterans Health Affairs	Afton Wagner	
Anna McCollister*	Individual		

\* HITAC Member \*\* HITAC Federal Representative





# Task Force Charge, Timeline and Workplan

Tricia Lee Rolle, Senior Advisor, ONC

Shelly Spiro, Co-Chair

# Pharmacy Interoperability and Emerging Therapeutics Task Force 2023 Charge

**Overarching charge:** Identify recommendations to support interoperability between pharmacy constituents, and the exchange of information necessary for medication management, patient safety and consumer engagement.

**Recommendations Due: November 9, 2023**

## **Specific charge:**

1. Public Health, Emergency Use Authorizations, and Prescribing Authorities
2. Identify opportunities and recommendations to improve interoperability between pharmacy constituents (prescribers, pharmacists, pharmacy benefit managers, dispensers, payers, intermediaries, PDMPs, public health agencies, HIEs, third party service providers, consumers, etc.) for pharmacy-based clinical services and care coordination.
3. Identify standards needs to support prescribing and management of emerging therapies including, but not limited to specialty medications, digital therapeutics, and gene therapies.
4. Identify policy and technology needs and considerations for direct-to-consumer medication services.





## Draft Timeline HITAC Task Force on Pharmacy Interoperability and Emerging Therapeutics

Proposed Meeting Date	Meeting #	Draft Agenda Items	SMEs Needed
<b><u>Pre-Work</u></b>		<ul style="list-style-type: none"> <li>Review Task Force Charter and Timeline</li> </ul>	
<b><u>Week 1</u></b>	Meeting 1 (June 21)	<ul style="list-style-type: none"> <li>Full TF Meets</li> <li>TF Kick-off Meeting</li> <li>TF Scope Overview</li> <li>TF Topic 1: SHORT-TERM Public Health, Emergency Use Authorizations, and Prescribing Authorities               <ol style="list-style-type: none"> <li>Identify critical standards and data needs for pharmacists and interested parties to participate in emergency use interventions.</li> <li>Are there actions ONC can take to enable data exchange in support of public health emergency use cases? For example, Test to Treat and COVID-19 treatment prescribing?</li> </ol> </li> <li>Discussion of draft recommendations</li> </ul>	
<b><u>Week 2</u></b>	Meeting 2 (June 28)	<ul style="list-style-type: none"> <li>Full TF Meets</li> <li>TF Topic1: SHORT-TERM Public Health, Emergency Use Authorizations, and Prescribing Authorities               <ol style="list-style-type: none"> <li>Identify critical standards and data needs for pharmacists and interested parties to participate in emergency use interventions.</li> <li>Are there actions ONC can take to enable data exchange in support of public health emergency use cases? For example, Test to Treat and COVID-19 treatment prescribing?</li> </ol> </li> <li>Discussion of draft recommendations</li> </ul>	(TBD) SME presentation on current state of pharmacists' actions supporting Emergency Use Authorizations and Prescribing Authorities <ul style="list-style-type: none"> <li>Retail or Community pharmacist perspective</li> <li>Network perspective</li> </ul>
<b><u>Week 3</u></b>	NO MEETING	Week of Independence Day	

## Draft Timeline HITAC Task Force on Pharmacy Interoperability and Emerging Therapeutics

Proposed Meeting Date	Meeting #	Draft Agenda Items	SMEs Needed
<b><u>Week 4</u></b>	Meeting 3 (July 12)	<ul style="list-style-type: none"> <li>Full TF Meets</li> <li>TF Topic 1: LONG-TERM Public Health, Emergency Use Authorizations, and Prescribing Authorities               <ol style="list-style-type: none"> <li>Recommendations to better integrate pharmacy systems and data for public health surveillance, reporting and public health interventions.</li> </ol> </li> <li>Discussion of draft recommendations</li> </ul>	(TBD) SME presentation on current state of pharmacist integration in public health reporting <ul style="list-style-type: none"> <li>Gov perspective (CDC)</li> <li>Immunization/ registry perspective</li> </ul>
<b><u>Week 5</u></b>	Meeting 4 (July 19)	<ul style="list-style-type: none"> <li>Full TF Meets</li> <li>TF Topic 1: LONG-TERM Public Health, Emergency Use Authorizations, and Prescribing Authorities               <ol style="list-style-type: none"> <li>Recommendations to better integrate pharmacy systems and data for public health surveillance, reporting and public health interventions.</li> </ol> </li> <li><b>Discussion of <u>draft final</u> recommendations for Topic 1</b></li> </ul>	(TBD) Additional SMEs if needed
<b><u>Week 6</u></b> Hans OOO	Meeting 5 (July 26)	<ul style="list-style-type: none"> <li>Full TF Meets</li> <li>TF Topic 2: Identify opportunities and recommendations to improve interoperability between pharmacy constituents for pharmacy-based clinical services and care coordination.               <ol style="list-style-type: none"> <li>How can ONC help facilitate adoption and use of standards to support data exchange for pharmacy-based clinical services?</li> </ol> </li> <li>Discussion of draft recommendations</li> </ul>	(TBD) SME presentation on current state of delivery of clinical pharmacy services
<b><u>Week 7</u></b> TLR OOO Hans OOO	NO MEETING (August 2)	Co-Chair and staff lead on leave	

## Draft Timeline HITAC Task Force on Pharmacy Interoperability and Emerging Therapeutics



Proposed Meeting Date	Meeting #	Draft Agenda Items	SMEs Needed
<u>Week 8</u>	Meeting 6 (August 9)	<ul style="list-style-type: none"> <li>• Full TF Meets</li> <li>• TF Topic 2: Identify opportunities and recommendations to improve interoperability between pharmacy constituents for pharmacy-based clinical services and care coordination.               <ul style="list-style-type: none"> <li>b) Which priority pharmacy-based clinical use cases should ONC focus on in the short-term and long-term?</li> </ul> </li> <li>• Discussion of draft recommendations</li> </ul>	(TBD) Additional SMEs if needed
<u>Week 9</u>	Meeting 7 (August 16)	<ul style="list-style-type: none"> <li>• Full TF Meets</li> <li>• TF Topic 2: Identify opportunities and recommendations to improve interoperability between pharmacy constituents for pharmacy-based clinical services and care coordination.               <ul style="list-style-type: none"> <li>c) What technology gaps exist for pharmacists to participate in value-based care?</li> </ul> </li> <li>• Discussion of draft recommendations</li> </ul>	(TBD) SME presentation on pharmacists and Value-Based Care (if not covered in Meeting 6 presentation)
	(August 17)	Task Force Update to the Full HITAC: Co-chairs will provide an update on TF progress to-date	
<u>Week 10</u>	Meeting 8 (August 23)	<ul style="list-style-type: none"> <li>• Full TF Meets</li> <li>• TF Topic 2: Identify opportunities and recommendations to improve interoperability between pharmacy constituents for pharmacy-based clinical services and care coordination.               <ul style="list-style-type: none"> <li>d) What can ONC do to address drug inventory transparency for prescribers and consumers?</li> </ul> </li> <li>• Discussion of <u>draft final</u> recommendations for Topic 2</li> </ul>	(TBD) SME Presentation on <ul style="list-style-type: none"> <li>• FDA shortage database</li> <li>• Other tech perspective</li> </ul>

## Draft Timeline HITAC Task Force on Pharmacy Interoperability and Emerging Therapeutics



Proposed Meeting Date	Meeting #	Draft Agenda Items	SMEs Needed
<b><u>Week 11</u></b>	Meeting 9 (August 30)	<ul style="list-style-type: none"> <li>Full TF Meets</li> <li>TF Topic 3: Identify standards needs to support prescribing and management of emerging therapies including, but not limited to specialty medications, digital therapeutics, and gene therapies.               <ol style="list-style-type: none"> <li>What standards gaps exist for the prescribing and management of:                   <ol style="list-style-type: none"> <li>specialty medications</li> </ol> </li> </ol> </li> <li>Discussion of draft recommendations for Topic 3</li> </ul>	(TBD) SME presentation on specialty medications <ul style="list-style-type: none"> <li>Workflow challenges</li> <li>NCPDP standards for specialty medication prescribing</li> </ul>
<b><u>Week 12</u></b>	NO MEETING	Week of Labor Day	
<b><u>Week 13</u></b> Shelly OOO	Meeting 10 (September 13)	<ul style="list-style-type: none"> <li>Full TF Meets</li> <li>TF Topic 3: Identify standards needs to support prescribing and management of emerging therapies including, but not limited to specialty medications, digital therapeutics, and gene therapies.               <ol style="list-style-type: none"> <li>What standards gaps exist for the prescribing and management of:                   <ol style="list-style-type: none"> <li>digital therapeutics</li> </ol> </li> </ol> </li> <li>Discussion of draft recommendations for Topic 3</li> </ul>	(TBD) SME presentation on digital therapeutics
	(September 14)	<ul style="list-style-type: none"> <li>Task Force Update to the Full HITAC: Co-chairs will provide an update on TF progress to-date</li> </ul>	
<b><u>Week 14</u></b>	Meeting 11 (September 20)	<ul style="list-style-type: none"> <li>Full TF Meets</li> <li>TF Topic 3: Identify standards needs to support prescribing and management of emerging therapies including, but not limited to specialty medications, digital therapeutics, and gene therapies.               <ol style="list-style-type: none"> <li>What standards gaps exist for the prescribing and management of:                   <ol style="list-style-type: none"> <li>gene therapies</li> </ol> </li> </ol> </li> <li>Discussion of draft recommendations for Topic 3</li> </ul>	(TBD) SME presentation on gene therapies <ul style="list-style-type: none"> <li>Standards and terminology perspective</li> </ul>

## Draft Timeline HITAC Task Force on Pharmacy Interoperability and Emerging Therapeutics

Proposed Meeting Date	Meeting #	Draft Agenda Items	SMEs Needed
<b><u>Week 15</u></b>	Meeting 12 (September 27)	<ul style="list-style-type: none"> <li>• Full TF Meets</li> <li>• TF Topic 3: Identify standards needs to support prescribing and management of emerging therapies including, but not limited to specialty medications, digital therapeutics, and gene therapies.               <ul style="list-style-type: none"> <li>a. What standards gaps exist for the prescribing and management of:                   <ul style="list-style-type: none"> <li>iv. Any other emerging therapeutic areas the TF has identified</li> </ul> </li> </ul> </li> <li>• <b>Discussion of <u>draft final</u> recommendations for Topic 3</b></li> </ul>	<ul style="list-style-type: none"> <li>• (TBD) Additional SMEs if needed</li> </ul>
<b><u>Week 16</u></b>	Meeting 13 (October 4)	<ul style="list-style-type: none"> <li>• Full TF Meets</li> <li>• TF Topic 4: Identify policy and technology needs and considerations for direct-to-consumer medication services.</li> <li>• Discussion of draft recommendations for Topic 4</li> </ul>	<ul style="list-style-type: none"> <li>• (TBD) Additional SMEs if needed</li> </ul>
<b><u>Week 17</u></b>	Meeting 14 (October 11)	<ul style="list-style-type: none"> <li>• Full TF Meets</li> <li>• TF Topic 4: Identify policy and technology needs and considerations for direct-to-consumer medication services.</li> <li>• <b>Discussion of <u>draft final</u> recommendations for Topic 4</b></li> </ul>	

## Draft Timeline HITAC Task Force on Pharmacy Interoperability and Emerging Therapeutics

Proposed Meeting Date	Meeting #	Draft Agenda Items	SMEs Needed
<b><u>Week 18</u></b> Hans OOO	Meeting 15 (October 18)	<ul style="list-style-type: none"> <li>• Full TF Meets</li> <li>• Discussion: TBD</li> </ul>	
	(October 19)	<ul style="list-style-type: none"> <li>• Task Force Update to the Full HITAC: Co-chairs will provide an update on TF progress to-date</li> </ul>	
<b><u>Week 19</u></b>	Meeting 16 (October 25)	<ul style="list-style-type: none"> <li>• Full TF Meets</li> <li>• <b>Discussion: Finalize all recommendations and the Task Force report to the HITAC</b></li> </ul>	
<b><u>Week 20</u></b>	Meeting 17 (November 1)	<ul style="list-style-type: none"> <li>• Full TF Meets</li> <li>• Discussion: TBD</li> </ul>	
<b><u>Week 21</u></b>	No Meeting (November 8)	<ul style="list-style-type: none"> <li>• Full HITAC Meeting this week on 11/9</li> </ul>	
	<b><u>(November 9)</u></b>	<b><u>Presentation of Final Recommendations and HITAC Vote</u></b>	



# Task Force Expectations on Recommendations

Hans Buitendijk, Co-Chair



# **SHORT-TERM Public Health, Emergency Use Authorizations, and Prescribing Authorities**

Shelly Spiro, Co-Chair

Hans Buitendijk, Co-Chair



# Pharmacy Interoperability and Emerging Therapeutics Task Force 2023 Discussion

## TOPIC 1 (for discussion June 21 and June 28):

### 1. Public Health, Emergency Use Authorizations, and Prescribing Authorities

#### Short-term

- a. Identify critical standards and data needs for pharmacists and interested parties to participate in emergency use interventions.
- b. Are there actions ONC can take to enable data exchange in support of public health emergency use cases? For example, Test to Treat and COVID-19 treatment prescribing?

*(FYI: The following will be discussed at meetings 3 and 4)*

#### Long-term

- a. *Recommendations to better integrate pharmacy systems and data for public health surveillance, reporting and public health interventions.*



# Public Comment

To make a comment please  
**Use the Hand Raise Function**

**If you are on the phone only, press “\*9” to raise your hand**

*(Once called upon, press “\*6” to mute/unmute your line)*

**All public comments will be limited to three minutes**

You may also email your public comment to [onc-hitac@accelsolutionsllc.com](mailto:onc-hitac@accelsolutionsllc.com)

*Written comments will not be read at this time,  
but they will be delivered to members of the task force and made part of the public record*



# Task Force Work Planning

Shelly Spiro, Co-Chair

Hans Buitendijk, Co-Chair

# Upcoming Meetings



Month	Task Force Meeting Dates	HITAC Meeting Date
June	28	
July	12, 19, 26	July 13
August	9, 16, 23, 30	August 17 (TF Update)
September	13, 20, 27	September 14 (TF Update)
October	4, 11, 18, 25	October 19 (TF Update)
November	1	November 9 (Final Recommendation and Vote)



**Adjourn**